Adderall Dosing Guidelines

General Dosing Principles

• Dosing is not differentiated by gender; however, weight‑based adjustments are required for children weighing less than 25 kg (≈55 lb) to limit single‑dose size and reduce adverse effects. 1

Starting Doses (All Patients)

• Initiate therapy with 2.5 mg of mixed amphetamine salts once or twice daily for any patient, regardless of gender. 2
• In children and adolescents, give the first 2.5 mg dose after breakfast and, if needed, a second 2.5 mg dose at midday. 3
• In adults, start with 5 mg once daily in the early morning; a 2.5 mg starting dose is also acceptable. 4
• Amphetamine formulations often allow a once‑daily regimen initially; increasing the morning dose can prolong therapeutic coverage. 2

Titration Schedule

• Increase the dose by 2.5–5 mg per dose each week until adequate symptom control is achieved or side‑effects appear. 1

• Typical weekly titration steps:

  Week	Dose (mg)
  1	2.5
  2	5
  3	7.5
  4	10
  …	Continue weekly increments as needed

Weight‑Based Considerations for Children

• Children < 25 kg should not receive single doses exceeding 10 mg. 1
• For children < 20 kg, omit the 15 mg and 20 mg dose increments during titration. 3
• Clinical trials in children < 25 kg have reached total daily doses up to 35 mg, though higher doses may be used if symptom improvement continues. 3
• No definitive maximum dose is established for very small children; clinicians should exercise caution. 3

Maximum Daily Doses

• The Physician’s Desk Reference lists 40 mg as the maximum total daily dose for amphetamines. 1
• Consensus in clinical practice also caps the upper range at 40 mg per day. 1
• Adults may be dosed up to 0.9 mg/kg/day, which generally corresponds to a 40 mg daily ceiling. 6
• In selected adult cases requiring extended coverage, total daily doses up to 65 mg have been used, provided lower doses were ineffective and higher doses did not produce adverse effects. 6

Gender Considerations

• Current guidelines do not recommend gender‑specific dosing adjustments. 1
• Emerging research suggests that girls with ADHD may exhibit a stronger response 2.5 hours after dosing but a weaker response at 12 hours compared with boys, indicating a possible need for different dosing schedules in the future. 7

Baseline and Ongoing Monitoring

• Obtain baseline blood pressure, pulse, height, and weight before initiating therapy. 1
• For children, check vital signs annually during routine examinations. 1
• For adults, monitor blood pressure and pulse quarterly. 1
• Record weight at every visit to objectively assess appetite suppression. 1

Clinical Pitfalls and Management Strategies

• Do not assume that higher doses will yield better outcomes when maximum recommended doses fail to produce improvement. 1
• If the highest recommended dose is ineffective, consider switching to an alternative stimulant rather than exceeding dose limits. 1
• Approximately 70 % of children respond to either dextroamphetamine or methylphenidate alone; response rates rise to about 90 % when both agents are trialed sequentially. 6
• Amphetamines are more likely than methylphenidate to cause appetite suppression, insomnia, and abdominal discomfort because of their longer half‑lives. 1
• Adjust the timing and strength of evening doses to minimize dinner‑time appetite suppression and delay of sleep onset. 3

Amphetamine Initiation and Titration After Methylphenidate Failure in Adults

Starting Dose Recommendations

• Begin amphetamine (mixed amphetamine salts) at 5 mg once daily in the early morning for most adults; a conservative option of 2.5 mg once daily or divided twice daily (after breakfast and at noon) is also acceptable. This recommendation is based on high‑quality clinical practice guidelines from the American Academy of Child and Adolescent Psychiatry. [8][9]

Titration Protocol

• Increase the dose by 5 mg each week until adequate symptom control is achieved or side effects limit further escalation. 9
• For patients who are particularly sensitive to stimulants, a slower titration of 2.5 mg per dose each week may be employed. [8][9]
• A typical weekly escalation schedule follows 5 mg → 10 mg → 15 mg → 20 mg, with further increments as needed up to the therapeutic range. 8

Maximum Dose Considerations

• The FDA‑approved maximum daily dose is 40 mg total for amphetamine products in adults. This limit is reflected in the Physician’s Desk Reference. 9

Conversion Guidance from Methylphenidate

• When switching from a failed methylphenidate trial, do not directly convert the prior methylphenidate dose; instead, start at the standard low amphetamine dose (5 mg or 2.5 mg) regardless of previous exposure. [8][9]

Safety Monitoring

Baseline Assessment Before Initiation

• Obtain baseline blood pressure, pulse, height, and weight during the physical examination. 9
• Screen for structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, essential hypertension, and a family history of sudden cardiac death or ventricular arrhythmia (general clinical practice; citations pertain to vital‑sign baseline). 9

Ongoing Monitoring During Treatment

• Check blood pressure and pulse quarterly throughout therapy to detect cardiovascular effects. 9
• Monitor weight at each visit to evaluate for appetite suppression. (General practice; no specific citation required beyond the quarterly vitals.)

Formulation and Dosing Frequency Considerations

• Amphetamine’s longer half‑life often permits once‑daily dosing initially, which can simplify regimens compared with immediate‑release methylphenidate. 8
• Increasing the morning dose can extend therapeutic coverage throughout the waking day, reducing the need for multiple daily administrations. 8

Management of Inadequate Response at Maximum Dose

• If the 40 mg daily maximum does not yield benefit, clinicians should avoid automatic dose escalation beyond this limit. Instead, consider switching back to methylphenidate, trying a different formulation, or adding psychosocial interventions. 9

Evidence Strength

• The starting‑dose and titration recommendations derive from high‑quality clinical practice guidelines of the American Academy of Child and Adolescent Psychiatry, representing the strongest available evidence for adult ADHD pharmacotherapy. [8][9]